There is a number of BRD4 inhibitors available with some in clinical trials such as AZD5153 in relapsed/refractory (R/R) solid tumours and lymphoma, CPI0610 in R/R lymphoma and myelofibrosis, and INCB057643 in several tumour types [64]. This evidence concerns the gene BRD4 and myelofibrosis.